companies / formation-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
Formation Bio was listed in Felicis's portfolio, recorded 2026-09-30.
verified=2026-05-05 json
| total_raised | 372,000,000372.0M | ○ |
|---|---|---|
| founded | 2016 | |
| hq | New York NY | |
| industry | unknown | |
| stage | series-b+ |
Formation Bio is a tech-enabled biopharma in-licensing clinical-stage assets and using AI plus automated operations to run trials faster. Patients, partner pharma, and ultimately healthcare systems benefit from compressed timelines and lower trial costs. The company runs its own clinical-development operations rather than outsourcing to CROs.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-06-01 | series-d+ | 372,000,000372.0M | null | ○ |
| investor | src |
|---|---|
| Andreessen Horowitz | ○ |
| Felicis | ○ |
Vercel, Next.js, Afterpay, Sanity, Sanity.io, PHP, React, Webpack, @stripe/stripe-js
| fact | status | src |
|---|---|---|
| Series D+, $372.0M | attributed | ○ |
| Investor Felicis | sourced | WEB |
| existence | self-reported | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-09-30provenance_investor_felicis: unknown → sourced, WEB 2026-09-30 | provenance_investor_felicis | unknown → sourced | WEB 2026-09-30 |
| 2026-09-27latest_round: series-d+, $372.0M, 2024-06-01, lead: a16z → series-d+, $372.0M, 2024-06-01, lead: null, ○ 2026-05-05 | latest_round | series-d+, $372.0M, 2024-06-01, lead: a16z → series-d+, $372.0M, 2024-06-01, lead: null | ○ 2026-05-05 |
Records begin 2026-09-24. all_changes